RHOPRESSA

Peak

netarsudil

Alcon
NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Clinical Trials (2)

NCT06865144Phase 4Recruiting

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Started Jun 2025
70 enrolled
Primary Open Angle Glaucoma or Ocular Hypertension
NCT06394973Phase 2Completed

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Started Aug 2024

Loss of Exclusivity

LOE Date
Mar 14, 2034
97 months away
Patent Expiry
Mar 14, 2034

Patent Records (5)

Patent #ExpiryTypeUse Code
8450344
Jul 11, 2026
SubstanceProduct
U-1524
11021456
Jul 11, 2026
U-1524
9096569
Jul 11, 2026
SubstanceProduct
U-1524
10532993
Jul 11, 2026
U-1524
10882840
Jul 11, 2026
U-1524
Company
Alcon
Alcon
FORT WORTH, TX
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers